Effective as of May 2, 2017, the board of Artelo Biosciences, Inc. increased its size from two members to four members and appointed Connie Matsui as a member of the board and the chair of the board and Steven Kelly as a member of the board to serve in such capacity for a period of four years, subject to their earlier resignation or removal. Ms. Matsui currently serves as the chair of the board at Halozyme and has been active on a number of not-for-profit boards. Since 2012, Mr. Kelly has been the principal of Kelly BioConsulting, LLC, and serves as an independent consultant providing strategic direction and guidance to a variety of life sciences companies. Most recently, Mr. Kelly was the founding CEO of Pinteon Therapeutics. Prior to this he held a number of leadership positions in the biotechnology industry including: CEO, Theracrine; CCO, BioVex; CEO, Innovive Pharmaceuticals; as well as various commercial and manufacturing roles at Sanofi, IDEC Pharmaceuticals and Amgen.